165 related articles for article (PubMed ID: 38646155)
1. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in
Tozuka T; Noro R; Yoshida K; Takahashi S; Hirao M; Matsuda K; Kato Y; Nakamichi S; Takeuchi S; Matsumoto M; Miyanaga A; Kunugi S; Honda K; Adachi J; Seike M
JTO Clin Res Rep; 2024 Apr; 5(4):100668. PubMed ID: 38646155
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
3. The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated
Murakami Y; Sonoda K; Abe H; Watari K; Kusakabe D; Azuma K; Kawahara A; Akiba J; Oneyama C; Pachter JA; Sakai K; Nishio K; Kuwano M; Ono M
Oncotarget; 2017 Sep; 8(41):70736-70751. PubMed ID: 29050315
[TBL] [Abstract][Full Text] [Related]
4. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
5. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).
Bracht JWP; Karachaliou N; Berenguer J; Pedraz-Valdunciel C; Filipska M; Codony-Servat C; Codony-Servat J; Rosell R
Int J Biol Sci; 2019; 15(12):2607-2614. PubMed ID: 31754333
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
8. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
[TBL] [Abstract][Full Text] [Related]
9. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
[TBL] [Abstract][Full Text] [Related]
10. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.
Ichihara E; Westover D; Meador CB; Yan Y; Bauer JA; Lu P; Ye F; Kulick A; de Stanchina E; McEwen R; Ladanyi M; Cross D; Pao W; Lovly CM
Cancer Res; 2017 Jun; 77(11):2990-3000. PubMed ID: 28416483
[TBL] [Abstract][Full Text] [Related]
11. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.
Olgen S; Biltekin Kaleli SN; Karaca BT; Demirel UU; Bristow HK
Curr Med Chem; 2023 Jun; ():. PubMed ID: 37365789
[TBL] [Abstract][Full Text] [Related]
13. Characterization of
Emdal KB; Dittmann A; Reddy RJ; Lescarbeau RS; Moores SL; Laquerre S; White FM
Mol Cancer Ther; 2017 Nov; 16(11):2572-2585. PubMed ID: 28830985
[TBL] [Abstract][Full Text] [Related]
14. Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Kosibaty Z; Brustugun OT; Zwicky Eide IJ; Tsakonas G; Grundberg O; De Petris L; McGowan M; Hydbring P; Ekman S
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884490
[TBL] [Abstract][Full Text] [Related]
15. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Hsu CC; Liao BC; Liao WY; Markovets A; Stetson D; Thress K; Yang JC
J Thorac Oncol; 2020 Jan; 15(1):50-61. PubMed ID: 31557536
[TBL] [Abstract][Full Text] [Related]
16. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
[TBL] [Abstract][Full Text] [Related]
17. DUSP1 Promotes Osimertinib Drug-Tolerant Persistence by Inhibiting MAPK/ERK Signaling in Non-small Cell Lung Cancer.
He W; Liu P; Lei Q; Xu J; Liu L
Mol Biotechnol; 2024 Mar; ():. PubMed ID: 38551790
[TBL] [Abstract][Full Text] [Related]
18. Feiyiliu Mixture sensitizes EGFR
Shi J; Hao S; Liu X; Li Y; Zheng X
Front Pharmacol; 2023; 14():1093017. PubMed ID: 36744262
[No Abstract] [Full Text] [Related]
19. Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.
Li L; Li Z; Lu C; Li J; Zhang K; Lin C; Tang X; Liu Z; Zhang Y; Han R; Wang Y; Feng M; Zhuang Y; Hu C; He Y
Commun Biol; 2022 Feb; 5(1):155. PubMed ID: 35197546
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
